Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C
New Drug's Clinical Evalutaion of Critical Disease;

..............page:161-164

A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment
Chen Zhiwei;,Hu Peng;,Ren Hong;

..............page:165-169

HCV infection and specific T lymphocyte immunity
Shi Jijing;,Zhang Jiyuan;,Zhang Xuexiu;,Wang Fusheng;

..............page:170-174

Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-a-2b and ribavirin
wang mao rong ;, zhang zuo ;, yang zhi guo ;, li ping ;, gao lei ;, chen xiao hui ;, wang jie ;, xiong xi ;, wang shou ming ;

..............page:175-180

Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy
ke ying chun ;, li ling hua ;, hu feng yu ;, he yan ;, lan zuo ;, chen xie jie ;, tang xiao ping ;, cai wei ping ;

..............page:181-185

Binding characteristics of chemosynthetic Ac-SDKP analogue FAM-Aca-SDKP to hepatic stellate cell-T6 cells
Zhou Da;,He Lingnan;,Wang Jing;,Ding Yongnian;,Chen Yuanwen;,Fan Jiangao;

..............page:186-190

Effect of high fat on fibrosis in rat hepatic stellate cells
Yuan Ji;,Liu Yanyan;,Ma Xuejiao;,Li Jiabin;

..............page:191-195

The regulation of CD44 expression by new tumor suppressor gene Arid2 and the influence of Arid2 on the invasion and metastasis in hepatocellular carcinoma cells
tian ling ;, duan yu jie ;, nie li zhu ;, li zhi ;, chen zhen ;, gao qing zhu ;, yang yi ;, tang ni ;, zheng jian ;

..............page:196-201

Extracellular Y-box binding protein-1 promotes proliferation and metastasis of HepG2 cells through Notch3 receptor
shi jing ;, li pu ;, zou zuo ;, chen pu ;, zhang li ping ;

..............page:202-206

Risk factors for short-term outcome of patients with HBV-related acute-on-chronic liver failure
li chen ;, lv zuo ;, zhu bing ;, wan zhi hong ;, liu wan zuo ;, guo li ;, you shao li ;, xin shao jie ;

..............page:207-213

Protective effect of Angelica sinensis polysaccharide against liver injury induced by D-galactose in aging mice and its mechanisms
xia zuo zuo ;, fan yan ling ;, jia dao yong ;, zhang meng si ;, zhang yan yan ;, li jing ;, jing peng wei ;, wang zuo ;, wang ya ping ;

..............page:214-219

Effect of chitooligosaccharide on hepatic triglyceride metabolism and related mechanisms
Wang Jian;,Jiang Man;,Xin Yongning;,Geng Ning;,Li Xuejie;,Xuan Shiying;

..............page:220-224

An investigation of paths for nutritional risk screening in patients with liver cirrhosis
Zhu Ming;,Zhao Changqing;,Ping Jian;,Zhou Yang;,Xu Lieming;

..............page:225-227

One case of newly-onset liver cancer and dual drug-resistance during treatment of hepatitis B cirrhosis with nucleos(t)ide analogues
Li Chunyan;,Pan Junyan;,Yang Aiping;

..............page:228-229

Which animal models of nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) have more practical value in experimental investigations?
Duan Nana;,Wu Jian;

..............page:230-233

Biomarkers of renal impairment and their application in renal function monitoring during treatment with nucleos(t)ide analogues
Li Huashan;,Ma Hong;

..............page:234-236

Role of lipin-1 in the pathogenesis of alcoholic fatty liver disease
li yuan yuan ;, zhou jun ying ;

..............page:237-240